FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
Italy Fines Apple €98.6 Million Over App Store Dominance 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
CAMBRIDGE, Mass., Feb. 08, 2016 -- Editas Medicine, Inc. (NASDAQ:EDIT) today announced the closing of its initial public offering of 6,785,000 shares of its common stock at a public offering price of $16.00 per share, before underwriting discounts and commissions, including 885,000 additional shares of common stock issued upon the exercise in full by the underwriters of their over-allotment option. All of the shares in the offering were sold by Editas Medicine. The shares began trading on the NASDAQ Global Select Market on February 3, 2016.
Morgan Stanley and J.P. Morgan acted as joint book-running managers for the offering. Cowen and Company acted as lead manager, and JMP Securities acted as co-manager for the offering.
A registration statement relating to the securities being sold in this offering was filed with and declared effective by the Securities and Exchange Commission. This offering was made only by means of a prospectus. Copies of the final prospectus relating to this offering may be obtained from Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, or from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (866) 803-9204.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.
About Editas Medicine
Editas Medicine is a leading genome editing company dedicated to treating patients with genetically defined diseases by correcting their disease-causing genes. The company was founded by world leaders in genome editing, and its mission is to translate the promise of genome editing science into a broad class of transformative genomic medicines to benefit the greatest number of patients.
Media Contact Dan Budwick Pure Communications, Inc. (973) 271-6085 [email protected] Investor Contact Jesse Baumgartner Stern Investor Relations, Inc. (212) 362-1200 [email protected]
